Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21763648 | 0.85 | GSK3A (0.45) | HTR2CHCRTR1HCRTR2EHMT2BRD4 | |
| SCHEMBL2265479 | 0.80 | HCRTR2 (0.50) | HCRTR1HCRTR2EHMT2BRD4MEN1 | |
| SCHEMBL7407552 | 0.80 | HCRTR2 (0.50) | HCRTR1HCRTR2EHMT2BRD4MEN1 | |
| SCHEMBL27091858 | 0.77 | HCRTR1 (0.58) | HCRTR1HCRTR2 | |
| SCHEMBL2900232 | 0.77 | GSK3A (0.43) | HTR2CHCRTR1HCRTR2EHMT2MEN1 | |
| SCHEMBL2900230 | 0.77 | GSK3A (0.43) | HTR2CHCRTR1HCRTR2EHMT2MEN1 | |
| SCHEMBL21538655 | 0.76 | LMNA (0.50) | HCRTR1HCRTR2EHMT2BRD4MEN1 | |
| SCHEMBL2338116 | 0.76 | HCRTR1 (0.53) | HCRTR1HCRTR2MEN1KMT2A | |
| SCHEMBL2341733 | 0.73 | HCRTR1 (0.42) | HCRTR1HCRTR2EHMT2BRD4MEN1 | |
| SCHEMBL104187 | 0.72 | SIGMAR1 (0.51) | HTR2CSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623863-B2 | Disubstituted azepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| EP-2348846-B1 | DISUBSTITUTED AZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-08-28 | — | — | EP | disclosed |
| US-20110207715-A1 | Disubstituted Azepan Orexin Receptor Antagonists | MERCK SHARP & DOHME LLC | 2011-08-25 | — | — | US | disclosed |
| WO-2010048017-A1 | DISUBSTITUTED AZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207715-A1 | Disubstituted Azepan Orexin Receptor Antagonists | HCRTR2, HCRTR1, OXTR | HTR2C 44/4885HCRTR1 2/4885HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.